PerkinElmer Launches Automated Workstation for Improved Process Development of Protein Therapeutics

PALM SPRINGS, Fla. --(Business Wire)--

PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment announced the launch of the JANUS^® BioTx Pro^TM automated workstation for improved process development of protein therapeutics at the 12^th Annual Protein Science Week (PepTalk), January 21-25 in Palm Springs, Florida at booth #312. Designed for high throughput, small scale protein purification, it is the only workstation that accommodates multiple chromatography modes (column, tip and batch) eliminating the need for multiple instruments, resulting in more efficient and cost effective sample processing.

The JANUS(R) BioTx Pro(TM) automated workstation for improved process development of protein therapeutics (Photo: Business Wire)

"Sample preparation for protein characterization can be a time cnsuming and tedious process," said Kevin Hrusovsky, president Life Sciences and Technology, PerkinElmer "Automating this function frees up valuable research time and enables scientists to obtain critical information earlier in the protein development pipeline. This is particularly important to support quality by design experimentation in both upstream and downstream processes to improve product quality and reduce development time."

The JANUS BioTx Pro enables small scale purification of µg to mg proteins on one system instead of three individual dedicated systems, supporting the use of commercially available plate and column based screening tools like GE PreDictor^™ plates, PhyNexus PhyTip® columns and Atoll columns. Applications for the workstation include resin binding studies and conditions screening.

On January 24, at 9:50am, at the PepTalk Conference, Jeremy Lambert, Portfolio Director, Automation, will present a talk on PerkinElmer's Automation and microfluidics technologies including how the JANUS Biotx Pro saves researchers time by automating sample preparation for protein characterization.

PerkinElmer has a portfolio of solutions across the biotherapeutics workflow, from target identification, cloning and expression to safety testing and quality control, to help ensure the consistent, reproducible results that biotherapeutics research and patient safety considerations demand. The portfolio includes the LabChip^® GXII^TM benchtop microfluidic system for high throughput protein analysis and characterization, and AlphaLISA^® assays, a no-wash ELISA alternative technology for biomarker identification, safety testing and toxicity studies.

For more information about PerkinElmer's biotherapeutics solutions, please visit: http://www.perkinelmer.com/biotherapeutics

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $1.9 billion in 2011, has about 7,400 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.